Area of research
Endocrinology, Diabetes and Metabolism · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Diabetes Treatment and Management, Cardiovascular Function and Risk Factors, Hyperglycemia and glycemic control in critically ill and hospitalized patients, and Diabetes, Cardiovascular Risks, and Lipoproteins.
Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice-Insights From the AROS Database.
Cardiovascular events and mortality among patients and controls with calcified carotid artery atheromas on panoramic radiographs: a 10-year follow-up of the PAROKRANK study
Dysglycaemia and incident aortic stenosis: a cohort study.
The recent renewed interest among cardiologists in detecting and preventing diabetes is welcomed.
Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus
Endodontic Inflammatory Disease and Future Cardiovascular Events and Mortality: A Report from the PAROKRANK Study.
High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk Factors.
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure.
Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006–2019: a registry-based cohort study
Impact Analysis of Heart Failure Across European Countries: An ESC-HFA Position Paper
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study ( <scp>US</scp> , <scp>UK</scp> and Sweden)
Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry)
Endodontic inflammatory disease: A risk indicator for a first myocardial infarction
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Lower cardiorenal risk with <scp>sodium‐glucose</scp> cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry
Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504-1511.
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study.
Antiphospholipid Antibodies in Patients With Myocardial Infarction.
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs